FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug

benzinga.com/news/fda/25/10/48506679/fda-pushback-prompts-akebia-to-drop-broad-label-pursuit-for-kidney-disease-drug

Akebia Therapeutics Inc. (NASDAQ:AKBA) stock is trading lower on Wednesday.
The kidney disease company met with the U.S. Food and Drug Administration (FDA) and has not reached an agreement on a path forward for the VALOR trial design, which involves the use of vadadustat to treat anemia…

This story appeared on benzinga.com, 2025-10-29 18:13:46.
The Entire Business World on a Single Page. Free to Use →